Biogen Idec

Biogen Idec acquires full rights of Tysabri from Elan

Wednesday, February 6, 2013 11:41 AM

Biogen Idec, an independent biotechnology company, has agreed to purchase biotech Elan’s full strategic, commercial and decision-making rights to Tysabri.

More... »

Biogen Idec to discontinue development of ALS drug

Friday, January 4, 2013 10:29 AM

Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

More... »

Biogen Idec, Isis collaborate on antisense programs for neurological disorders

Monday, December 10, 2012 11:54 AM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into a global collaboration agreement to discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders. Biogen Idec and Isis are already collaborating on antisense drugs to treat spinal muscular atrophy and myotonic dystrophy type 1 under previously established collaborations.

More... »

Nimbus Discovery names Lynch as executive chairman

Friday, November 2, 2012 03:04 PM

Nimbus Discovery, a biotechnology company based in Cambridge, Mass., has appointed Daniel S. Lynch to the company's board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., co-founder of Nimbus and partner at Atlas Venture, who will remain on the board.

More... »

Astellas Pharma Europe appoints Wood as senior director, market access

Monday, August 20, 2012 03:21 PM

Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Dr, Susan Wood as senior director, market access.

More... »

Biogen Idec, Regulus to explore microRNA biomarkers for monitoring MS

Friday, August 17, 2012 11:38 AM

Regulus Therapeutics, a San Diego-based biopharmaceutical company focused on medicines targeting microRNAs, has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis (MS).

More... »

Biogen Idec to collaborate to sequence genomes of ALS patients

Tuesday, July 17, 2012 02:54 PM

Biogen Idec has entered into a research collaboration with premier academic and research institutions to sequence the genomes of up to 1,000 patients with amyotrophic lateral sclerosis (ALS) in an effort to gain a deeper understanding about the fundamental genetic causes of ALS.

More... »

Biogen Idec, Isis partner on antisense program targeting myotonic dystrophy

Friday, June 29, 2012 03:12 PM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into an exclusive, worldwide option and collaboration agreement to develop and commercialize a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), also known as Steinert disease.

More... »

Seven global biopharmas form neuroscience consortium

Wednesday, June 20, 2012 02:56 PM

Seven global biopharmaceutical companies have formed the Massachusetts Neuroscience Consortium, which will fund pre-clinical neuroscience at Massachusetts academic and research institutions. Participants include Abbott, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals.

More... »

Oral BG-12 garners positive phase III results in MS

Wednesday, April 25, 2012 12:15 PM

In a second phase III trial (CONFIRM), Biogen Idec’s oral BG-12 (dimethyl fumarate) demonstrated efficacy across a variety of clinical and radiological outcome measures, as well as favorable safety and tolerability profiles in patients with relapsing-remitting multiple sclerosis (RRMS).

More... »